Australia’s active vaccine safety system
Data on this page show the responses of individuals who received the Pfizer JN.1 COVID-19 vaccine (age 12 years and over formulation) and completed an AusVaxSafety survey sent on day 3 after vaccination. These data give a profile of what to expect in the days following Pfizer JN.1 COVID-19 vaccination and can assist when planning for your Pfizer JN.1 COVID-19 vaccination. Data on this page are updated monthly.
AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.
Information about COVID-19, vaccines and recommendations for vaccination from the Australian Immunisation Handbook
